Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Antibody-Drug conjugate IM-1617 enters human trials for advanced cancers

NCT ID NCT07578571

Recruiting now Disease control Sponsor: Immunome, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new drug called IM-1617 in people with advanced solid tumors (cancers that have spread or can't be removed by surgery). The study has two parts: first, finding a safe dose, then testing that dose in more people to see how well it works and how safe it is. About 175 participants with colorectal, lung, breast, esophageal, or stomach cancer will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
IM-1617 (an antibody-drug conjugate)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have spread or cannot be removed.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is not yet known if IM-1617 will effectively shrink tumors. Side effects are possible, and the drug may not work for all cancer types studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cancer colorectal cancer colorectal neoplasm esophageal cancer Esophageal Neoplasms gastric cancer gastric neoplasm neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER CANCER COLORECTAL CANCER ESOPHAGEAL CANCER NON-SMALL CELL LUNG CANCER STOMACH CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Florida Cancer Specialists & Research Institute - Sarasota Cattlemen

    RECRUITING

    Sarasota, Florida, 34239, United States

  • NEXT Dallas

    RECRUITING

    Irving, Texas, 75039, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.